PARKINSON’S DISEASE MODIFICATION THROUGH ABL KINASE INHIBITION (ID 2360)

Presenter
Authors
Gallery Display
Onsite Oral and Gallery PDF
Availability
Available at any time. Text to 9174940831 or email to mhwerner@inhibikase.com
Audio MP3

Availability

Available at any time. Text to 9174940831 or email to mhwerner@inhibikase.com
Hide

Audio MP3

Hide

Previous ePoster
TARGETING REACTIVE ASTROCYTOSIS FOR NOVEL BIOMARKERS OF DISEASE SEVERITY IN MULTIPLE SYSTEM ATROPHY (ID 2359)

Next ePosters
PROTEOMIC CORRELATES OF AMYLOID BETA AND TAU IN CSF. A MONOZYGOTIC TWIN STUDY (ID 2408)
GSK-3ALPHA IN HUNTINGTON’S DISEASE (ID 1797)
UNDERSTANDING SYNAPTIC INTEGRITY IN ALZHEIMER’S BRAIN WITH UCB-J (ID 2266)
MOLECULAR COMPOSITION OF ENTORHINAL SYNAPSES IN PRIMARY AGE-RELATED TAUOPATHY AND ALZHEIMER’S DISEASE (ID 2267)
INCREASED SV2A-PET AND EXCITATORY POSTSYNAPTIC POTENTIAL CORRELATES WITH RELEASE OF CSF NEUROGRANIN AND TAU IN APP KNOCK-IN MICE (ID 2268)
CHRONIC IN VIVO ALTERATIONS OF AΗ-Α PEPTIDE LEVELS PERTURB SYNAPTIC PLASTICITY AND IMPACT SPATIAL MEMORY. (ID 2271)
TRANSCRIPTOME ANALYSIS OF HIPPOCAMPUS OF APP KNOCK-IN ALZHEIMER MOUSE MODELS REVEALS AUTOPHAGY IMPAIRMENT LINKED WITH SYNAPTIC DYSFUNCTION (ID 2272)
AMYLOID SEEDING EMERGES AS A POTENTIAL TARGET FOR THE TREATMENT OF AMYLOIDOSIS (ID 2222)
SYNAPTIC ESTROGEN RECEPTOR ALPHA IMPROVES E46K-AMPLIFIED 3K ALPHA-SYNUCLEIN NEUROPATHOLOGY AND PHENOTYPES IN MICE (ID 2225)
FEASIBILITY AND SAFETY OF SIMULTANEOUSLY IMPLANTING AUTOLOGOUS REGENERATIVE PERIPHERAL NERVE TISSUE TO THE NUCLEUS BASALIS OF MEYNERT AND SUBSTANTIA NIGRA IN PATIENTS WITH PARKINSON’S DISEASE (ID 2227)